Who is eligible for clinical trial NCT07632014?

Participants must meet protocol criteria for Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07632014 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-03

CAYA Cancer Prospective Cohort Study (NCT07632014)

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Resonance, Inc.

🩺 Plain-English Summary (8th-Grade Level)

Cancer is a leading cause of illness and death among children, adolescents, and young adults(CAYAs), especially in low- and middle-income countries(LMICs), where access to timely diagnosis and treatment is often limited. As a result, patients in these settings may experience higher rates of treatment complications, interruptions, and poorer outcomes compared with those in high-income countries (HICs). This is a prospective, multicenter observational study that will follow children, adolescents, and young adults(CAYAs) with cancer who are receiving routine care at participating hospitals in low - and middle - income countries(LMICs). The study does not involve experimental treatments or changes to standard medical care. Information will be collected from medical records and from questionnaires that address access to care and social factors affecting treatment. By describing treatment outcomes and the challenges patients and families face during cancer care, this study aims to provide data that can help inform future efforts to improve access to care and cancer outcomes in resource-limited settings.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (1 items).

Location: Yeolyan Center for Cancer and Blood Disorders — Yerevan

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Subjects must meet all the following criteria to be included in this study:
Age 0 to 21 years at study enrollment.
Diagnosed with cancer and receiving active treatment or undergoing follow-up at the participating sites. a. Note: Patients seen solely for consultation or diagnostic evaluations without subsequent treatment and those who have been off treatment for more than 5 years and are seen only for survivorship follow-up are not considered as meeting this criterion.
Willingness to provide informed consent/assent. For minors incapable of providing assent, or individuals unable to provide consent, consent must be obtained from a legal representative and in accordance with local requirements.

Usually NOT eligible if any of the following apply:

Exclusion Criteria: Subjects meeting any of the following criteria must be excluded from this study: 1\. Any medical or psychological condition that, in the investigator's opinion, might compromise the ability of the patient to provide assent/informed consent/assent.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (3 Sites)

Yeolyan Center for Cancer and Blood Disorders — Yerevan,
The Children's Cancer Hospital Egypt 57357 — Cairo,
Unidad Nacional de Oncología Pediátrica (UNOP) — Guatemala City,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗